A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.;Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Dialysis (ASCEND-D)

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2021
This article has no abstract
Epistemonikos ID: a9e7da00af10472a400908c032394d3a294300f1
First added on: Apr 11, 2025